For anyone in Brusy looking to source CJC-1295, the first thing to know is that this compound is available only through an online research supply market. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. Separating genuine research-grade CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Brusy researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Brusy comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors starts with the COA: request the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger dangerous inflammatory cascades even at minute levels. Red flags in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Brusy
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not a licensed human medication and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
